Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

Quick Access

Favorites
Most Used

All Specialties

OpiCalc Logo
Clinical CalculatorsDrugsGuidelines
SpecsDrugsGuides
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Registry Hub
Peer-Reviewed Evidence
HomeDrug RegistryCompareAEROLATE vs ACCURBRON
Comparative Pharmacology

AEROLATE vs ACCURBRON Comparison

Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.

Clinical EssentialsPharmacokineticsSpecial PopulationsSafety & MonitoringPregnancy & LactationClinical Insights
Differential Analysis

AEROLATE vs ACCURBRON

Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.

View AEROLATE Monograph View ACCURBRON Monograph
AEROLATE
Bronchodilator
Category C
ACCURBRON
Methylxanthine Bronchodilator
Category C
TL;DR — Key Differences
  • Drug class: AEROLATE is a Bronchodilator; ACCURBRON is a Methylxanthine Bronchodilator.
  • Half-life: AEROLATE has a half-life of Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days; ACCURBRON has Terminal elimination half-life: 8-12 hours (healthy adults), prolonged to 15-20 hours in hepatic impairment. Clinical context: Supports twice-daily dosing in most patients..
  • No direct drug-drug interaction has been documented between AEROLATE and ACCURBRON.
  • Pregnancy: AEROLATE is rated Category C; ACCURBRON is rated Category C.

Last clinically reviewed: July 2026 · OpiCalc Medical Review Team

Clinical Essentials

AEROLATE
ACCURBRON
Mechanism of Action
AEROLATE

Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.

ACCURBRON

Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors (M1-M3), reducing vagal tone and bronchoconstriction. Albuterol is a beta2-adrenergic agonist that stimulates adenylate cyclase, increasing c AMP and causing bronchodilation.

Indications
AEROLATE

FDA-approved: Treatment of asthma and chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity, bradycardia in preterm infants

ACCURBRON

FDA-approved: Treatment of COPD exacerbations,Off-label: Acute asthma exacerbations

Standard Dosing
AEROLATE

For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.

ACCURBRON

Acetylcysteine 600 mg orally once daily, or 200 mg orally three times daily. Also available as 10% or 20% solution for inhalation: 3-5 m L of 20% solution or 6-10 m L of 10% solution nebulized three to four times daily.

Direct Interaction
AEROLATE
No Direct Interaction
ACCURBRON
No Direct Interaction

Pharmacokinetics

AEROLATE
ACCURBRON
Half-Life
AEROLATE

Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days

ACCURBRON

Terminal elimination half-life: 8-12 hours (healthy adults), prolonged to 15-20 hours in hepatic impairment. Clinical context: Supports twice-daily dosing in most patients.

Metabolism
AEROLATE

Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by xanthine oxidase and N-acetyltransferase. Metabolites excreted renally.

ACCURBRON

Ipratropium: minimally metabolized via hydrolysis and conjugation; Albuterol: primarily metabolized by catechol-O-methyltransferase (COMT) and sulfation.

Excretion
AEROLATE

Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other

ACCURBRON

Renal: 60-70% as unchanged drug; biliary/fecal: 20-30% as metabolites; <10% in feces as unchanged drug.

Protein Binding
AEROLATE

65% bound to albumin

ACCURBRON

85-90% bound to albumin.

VD (L/kg)
AEROLATE

2.5 L/kg (extensive tissue distribution, suggests high lung penetration)

ACCURBRON

0.8-1.2 L/kg (wide distribution into tissues, including lungs).

Bioavailability
AEROLATE

Oral: 40% (first-pass metabolism); Inhaled: 20% (lung deposition)

ACCURBRON

Oral: 60-80% (first-pass metabolism reduces bioavailability).

Special Populations

AEROLATE
ACCURBRON
Renal Adjustments
AEROLATE

No dose adjustment required for renal impairment. Drug is primarily hepatically metabolized and renally excreted as inactive metabolites; however, significant accumulation is not expected in renal dysfunction.

ACCURBRON

No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing oral dose by 50% or extending interval due to accumulation of acetylcysteine metabolites.

Hepatic Adjustments
AEROLATE

Child-Pugh Class A: No dose adjustment. Class B: Reduce dose to 50% of normal, monitor for adverse effects. Class C: Use with caution; reduce dose to 25-50% and monitor closely. Specific data for AEROLATE limited; adjust based on clinical response and tolerance.

ACCURBRON

No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to potential increased exposure.

Pediatric Dosing
AEROLATE

Children 4-11 years: 1-2 inhalations (90 mcg each) twice daily; maximum 2 inhalations twice daily. Children 12 years and older: Same as adult dosing. Administer via inhaler with spacer for optimal delivery. Weight-based dosing not typically used; fixed doses per age group.

ACCURBRON

Inhalation: Infants and children: 1-2 m L of 20% solution or 2-4 m L of 10% solution nebulized three to four times daily. Oral: Not typically recommended for chronic use; for acetaminophen overdose, weight-based dosing is used.

Geriatric Dosing
AEROLATE

No specific dose adjustment required. Use lowest effective dose due to potential for increased systemic exposure from reduced clearance and higher risk of adverse effects (e.g., osteoporosis, hyperglycemia). Monitor for cardiac effects and adrenal suppression.

ACCURBRON

No specific dose adjustment; monitor for adverse effects such as bronchospasm or nausea. Use with caution in elderly with renal impairment (refer to renal adjustment).

Safety & Monitoring

AEROLATE
ACCURBRON
Black Box Warnings
AEROLATE
FDA Black Box Warning

No FDA black box warning.

ACCURBRON
FDA Black Box Warning

No FDA boxed warning exists for this combination product.

Warnings/Precautions
AEROLATE

Monitor serum theophylline levels due to narrow therapeutic index (10-20 mcg/m L).,Risk of toxicity at high levels: seizures, arrhythmias, death.,Use with caution in patients with hepatic impairment, heart failure, fever, or elderly.,Cigarette smoking and certain drugs (e.g., rifampin, phenytoin) induce metabolism; others (e.g., cimetidine, macrolides) inhibit metabolism.

ACCURBRON

Paradoxical bronchospasm, cardiovascular effects (tachycardia, hypertension), worsening of narrow-angle glaucoma, urinary retention, hypokalemia, and immediate hypersensitivity reactions.

Contraindications
AEROLATE

Hypersensitivity to theophylline or any component.,Active peptic ulcer disease.,Uncontrolled seizure disorders.

ACCURBRON

Hypersensitivity to ipratropium, albuterol, or atropine; history of anaphylaxis to soya lecithin or related food products; narrow-angle glaucoma; prostatic hyperplasia or bladder neck obstruction (relative).

Adverse Reactions
AEROLATE
Data Pending
ACCURBRON
Data Pending
Food Interactions
AEROLATE

Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may potentiate CNS stimulation and toxicity. Food does not significantly affect absorption, but high-fat meals may delay absorption. Consistent dietary habits are recommended.

ACCURBRON

High-fat meals can increase absorption of theophylline; take on an empty stomach or with light snack for consistent effect. Avoid large amounts of charcoal-broiled foods as they may decrease drug levels. Caffeine-containing foods and beverages (coffee, tea, cola, chocolate) can potentiate side effects such as nervousness, tremor, and insomnia. Charbroiled meats and cruciferous vegetables (broccoli, Brussels sprouts) may induce metabolism and reduce effectiveness. Grapefruit juice may increase theophylline levels; avoid concurrent use.

Pregnancy & Lactation

AEROLATE
ACCURBRON
Teratogenic Risk
AEROLATE

AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theophylline crosses the placenta and can cause fetal tachycardia, jitteriness, and irritability; apneic episodes and respiratory failure reported in neonates exposed near term. Risk of preterm labor and low birth weight associated with maternal asthma exacerbation.

ACCURBRON

No adequate human data; animal studies show no evidence of teratogenicity. However, use only if clearly needed during pregnancy, especially first trimester.

Lactation Summary
AEROLATE

Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Peak milk levels occur 1-2 hours after maternal dosing. Estimated infant dose is about 1-10% of maternal weight-adjusted dose. Caution: irritability and jitteriness reported in breastfed infants. Avoid breastfeeding if maternal serum theophylline levels exceed 20 mcg/m L.

ACCURBRON

Not known if excreted in human breast milk. Caution advised; consider developmental benefits vs risks. M/P ratio not available.

Pregnancy Dosing
AEROLATE

Pregnancy may increase theophylline clearance (especially in second and third trimesters) due to increased renal perfusion and hepatic metabolism. Dose adjustments often required to maintain therapeutic levels. Initiate at standard dose and titrate based on serum levels and clinical response. Postpartum clearance decreases rapidly; doses should be reduced to pre-pregnancy levels within 2-4 weeks after delivery.

ACCURBRON

No dose adjustment routinely recommended; however, increased clearance may require monitoring for therapeutic effect.

Maternal Safety Status
AEROLATE
Category C
ACCURBRON
Category C

Clinical Insights

AEROLATE
ACCURBRON
Clinical Pearls
AEROLATE

AEROLATE (theophylline) has a narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders unless essential. Caution with hepatic impairment, heart failure, and in elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides, and CYP1A2 inhibitors increase levels; smoking and rifampin decrease levels.

ACCURBRON

Accurbron (theophylline) has a narrow therapeutic index; serum levels should be maintained between 5-15 mcg/m L. Hepatic metabolism is highly variable; monitor levels closely in patients with liver impairment, heart failure, or those on interacting drugs. Smoking induces metabolism, requiring higher doses. Use with caution in elderly and patients with seizure disorders or peptic ulcer disease. Do not crush or chew extended-release tablets.

Patient Counseling
AEROLATE

Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without informing your doctor, as smoking affects the drug's metabolism.,Keep a list of all medications you take, including over-the-counter drugs and herbal supplements.

ACCURBRON

Take exactly as prescribed; do not change dose without doctor approval.,Do not crush or chew sustained-release tablets.,Avoid excessive intake of caffeine (coffee, tea, cola, chocolate) as it may increase side effects like nausea, jitteriness, and insomnia.,Report any symptoms of toxicity: persistent nausea, vomiting, insomnia, rapid heartbeat, seizures.,Smoking or quitting smoking can affect theophylline levels; inform your doctor about any changes in smoking habits.,Keep regular appointments for blood tests to monitor drug levels.,Avoid taking other medications, including over-the-counter drugs and herbal supplements, without consulting your doctor.

Safety Verification

Known Interactions

AEROLATE Risks

No interactions on record

ACCURBRON Risks

No interactions on record

Compare Alternatives

Related Drug Comparisons

Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.

AEROLATE vs AEROLATE IIIBronchodilator
ACCURBRON vs AEROLATE IIIBronchodilator
AEROLATE vs AEROLATE JRBronchodilator
ACCURBRON vs AEROLATE JRBronchodilator
AEROLATE vs AEROLATE SRBronchodilator
ACCURBRON vs AEROLATE SRBronchodilator
AEROLATE vs AEROLONEBronchodilator
ACCURBRON vs AEROLONEBronchodilator
AEROLATE vs ALBUTEROLBeta-2 Adrenergic Agonist (Bronchodilator)
Clinical Q&A

Frequently Asked Questions

Common clinical questions about AEROLATE vs ACCURBRON, answered by our medical review team.

1. What is the main difference between AEROLATE and ACCURBRON?

AEROLATE is a Bronchodilator that works by Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.. ACCURBRON is a Methylxanthine Bronchodilator that works by Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors (M1-M3), reducing vagal tone and bronchoconstriction. Albuterol is a beta2-adrenergic agonist that stimulates adenylate cyclase, increasing c AMP and causing bronchodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.

2. Which is stronger: AEROLATE or ACCURBRON?

Potency comparisons between AEROLATE and ACCURBRON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.

3. What is the standard dosing for AEROLATE vs ACCURBRON?

The standard adult dose of AEROLATE is: For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.. The standard adult dose of ACCURBRON is: Acetylcysteine 600 mg orally once daily, or 200 mg orally three times daily. Also available as 10% or 20% solution for inhalation: 3-5 m L of 20% solution or 6-10 m L of 10% solution nebulized three to four times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.

4. Can you take AEROLATE and ACCURBRON together?

No direct drug-drug interaction has been formally documented between AEROLATE and ACCURBRON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.

5. Are AEROLATE and ACCURBRON safe during pregnancy?

The maternal-fetal safety profiles differ. AEROLATE is classified as Category C. AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theo. ACCURBRON is classified as Category C. No adequate human data; animal studies show no evidence of teratogenicity. However, use only if clearly needed during pregnancy, especially first trimester.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.